Transcoronary bone marrow-derived progenitor cells in a child with myocardial infarction: first pediatric experience.
BACKGROUND
Recent advances in stem cell therapy to restore cardiac function have great promise for patients with congestive heart failure after myocardial infarction in an adult population.


OBJECTIVE
We examined the benefits of bone marrow-derived progenitor cells treatment modality for the pediatric patient.


RESULTS
We present our first case of transcoronary autologous stem cell transplantation in a 9-year-old girl with refractory congestive heart failure secondary to myocardial infarction 1 year after transcatheter revascularization. The child received daily injections of granulocyte colony-stimulating factor for 3 days prior to the bone marrow aspiration. The bone marrow cells were isolated to constitute CD133+/CD34+ more than 90% of the total number. Subsequently, the progenitor cell suspension was injected via a transcoronary catheter without any complication. Three months after stem cell therapy, her cardiac function, assessed by both cardiac magnetic resonance and echocardiogram, has been improved with the left ventricular ejection fraction at 47% compared to the baseline of 30%.


CONCLUSIONS
This is the first reported pediatric case of successful transcoronary injection of bone marrow-derived progenitor cells for end-stage heart disease. The procedure is considered safe and feasible for the pediatric population.
Limsuwan
Alisa
A
Division of Pediatric Cardiology, Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. alimsuwan@yahoo.com
Pienvichit
Pavit
P
Limpijankit
Thosaphol
T
Khowsathit
Pongsak
P
Hongeng
Suradej
S
Pornkul
Ratanaporn
R
Siripornpitak
Suvipaporn
S
Boonbaichaiyapruk
Sarana
S
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis; D001854:Bone Marrow Cells / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000379:methods*; D006328:Cardiac Catheterization; D002469:Cell Separation / Q000379:methods; D002648:Child; D004452:Echocardiography; D005260:Female; D005434:Flow Cytometry; D006023:Glycoproteins / Q000032:analysis; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006333:Heart Failure / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009203:Myocardial Infarction / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D010455:Peptides / Q000032:analysis; D020127:Recovery of Function; D033581:Stem Cell Transplantation / Q000379:methods*; D013318:Stroke Volume; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left
D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D016179:Granulocyte Colony-Stimulating Factor